Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by stockpatrolon Oct 03, 2022 5:57pm

104 Views

Post# 35002692

AGN.c begun phase 1 study of their groundbreaking DMT treatm

AGN.c begun phase 1 study of their groundbreaking DMT treatment for post-stroke recovery

https://twitter.com/Psych_Fin/status/1577032702175629313

AGN.c will be the headline sponsor of Wonderland Miami Nov 3rd-5th, perhaps we can expect some results from their phase 1 DMT trials. AGN.c forsure one to watch in the psychedelic healthcare sector.

<< Previous

Bullboard Posts

Next >>

Full Circle Lithium goes global with its battery fire-fighter